Levofloxacin is the L-isomer of the racemic drug ofloxacin. The antibacterial activity of ofloxacin resides almost entirely in the L-isomer. Therefore, levofloxacin is, by its nature, twice as active as ofloxacin per unit of mass. 7
such as Chlamydia trachomatis, but has limited activity against anaerobic bacteria. 1,9 Figure 1 shows the cumulative distributions of minimum inhibitory concentrations (MICs) of levofloxacin in comparison with ciprofloxacin and moxifloxacin for wild-type populations of four aerobic bacterial pathogens known to cause external ocular infections. 11 A microorganism is defined as wild-type for a species by the absence of acquired and mutational resistance mechanisms to the corresponding drug. Clinical MIC breakpoints for levofloxacin against staphylococci, β-haemolytic streptococci, H. influenzae, Moraxella catarrhalis, members of the Enterobacteriaceae family and P. aeruginosa, as suggested by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), are ≤1mg/l and >2mg/l separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms, respectively, while those against S. pneumoniae are ≤2mg/l and >2mg/l, respectively. 12 Levofloxacin displays good activity against wild-type strains of P. aeruginosa (0.063-2mg/l) and is highly active against wild-type strains of H. influenzae (0.008-0.031mg/l), M. catarrhalis (0.016-0.063mg/l) and the Enterobacteriaceae, including Citrobacter spp., Enterobacter spp., E. coli, Klebsiella pneumoniae and Proteus mirabilis (0.016-0.25mg/l). In general, levofloxacin is more active than moxifloxacin (a newer fluoroquinolone), but less active than ciprofloxacin (an earlier fluoroquinolone) against these Gram-negative species. Levofloxacin also shows good in vitro activity against wild-type strains of a range of Gram-positive bacterial species, with MIC values of 0.064-0.5 for S. aureus, 0.5-2mg/l for S. pneumoniae and 0.25-2mg/l for S. pyogenes. In contrast, ciprofloxacin is less active against Gram-positive bacteria, while moxifloxacin has higher in vitro activity. 
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Resistance
Decreased susceptibility to levofloxacin (and other fluoroquinolones) can develop through two major mechanisms, namely alterations in the drug's target and alterations that affect the intracellular concentration of the drug.
Target-site alterations are linked to mutations in the quinolone-resistancedetermining region (QRDR) of the gyrA and parC genes. 7, 10 Such mutations usually result from errors during chromosome replication, but can also be acquired via horizontal gene transfer, which has been observed in S. pneumoniae and viridans group streptococci. 13, 14 A high level of resistance to levofloxacin requires mutations in more than one gene. 15 The second main mechanism of resistance, which is associated with a decrease in the intracellular concentration, results from changes in the outer membrane of bacteria (limited to Gram-negative bacteria) and/or drug efflux. 7 Recently, plasmid-mediated quinolone resistance genes (qnr) have been described in E. coli and other Enterobacteriaceae species. 16 The Qnr among the MSSA isolates (n=164) and MRSA isolates (n=33), respectively. 18 According to data from a German prospective surveillance study conducted in 2004 evaluating 436 S. aureus isolates recovered from patients with external ocular infections in 35 laboratories, the level of resistance to levofloxacin was 5% among the MSSA (n=380) and 53.6% among the MRSA (n=56). 19 Streptococcus pneumoniae: The emergence of fluoroquinolone-resistant strains of S. pneumoniae has been reported in recent years in some parts of the world, in particular in South-east Asia. 20, 21 However, the overall incidence of fluoroquinolone resistance among pneumococci seems to remain low. All 49 isolates collected during Ocular TRUST 1 were levofloxacin-susceptible. In addition, all archived 760 ocular isolates collected during the longitudinal TRUST surveillance programme between 1996 and 2006 were susceptible to levofloxacin, except one. 18 The German surveillance study found that 184/187 (98.4%) were susceptible. 19 Haemophilus influenzae: All isolates collected during Ocular TRUST 1 (n=32) were susceptible to levofloxacin, as were 355/356 (99.7%) of the archived isolates from TRUST, regardless of β-lactamase production. 18 The German surveillance study found that all 164 isolates examined showed susceptibility to levofloxacin. 19 Other ocular pathogens: Data from the German resistance surveillance study for ocular organisms indicated that none of the 46 E. coli isolates and 6/45 (13.3%) of the P. aeruginosa isolates were resistant to levofloxacin, 19 five of which were isolated from hospitalised patients.
Pharmacokinetic and Toxicological Properties
After a single drop of 0.5% levofloxacin ophthalmic solution applied to each eye of healthy volunteers, drug concentrations in the tear fluid remained above 2mg/l for at least six hours. 22 Following topical administration, the drug has also been demonstrated to effectively penetrate the cornea, and if the drug is frequently given over one hour, concentrations achieved in the anterior chamber of the eye were above the MICs of most ocular bacterial pathogens. [23] [24] [25] When combined with orally administered levofloxacin, adequate drug levels were also achieved in the vitreous cavity of the eye. 26 Topically applied fluoroquinolones have been considered to be more toxic to the corneal epithelium than other antibiotic agents. 27, 28 However, in a recently published study levofloxacin did not negatively influence epithelial wound healing. 29 Moreover, levofloxacin was shown to be less cytotoxic on human corneal keratocytes and epithelial cells than other fluoroquinolones, including gatifloxacin, moxifloxacin, ciprofloxacin and ofloxacin. 30 
Pharmacokinetic/Pharmacodynamic Relationships
The ratio between the 24-hour area under the serum concentration curve and MIC (AUC 24h /MIC) and the peak concentration/MIC (C max /MIC) for unbound drug are thought to be predictors of clinical and bacteriological efficacy. 31 However, the magnitude of the pharmacokinetic/pharmacodynamic (PK/PD) index needed seems to vary according to the type of quinolone, bacterial species and immune status. A C max /MIC ratio of >10
and an AUC 24h /MIC ratio of 100-125 has been reported to provide maximum bacterial eradication and to prevent resistance in critically ill patients with nosocomial lower respiratory tract infections caused by
Gram-negative bacteria such as P. aeruginosa. 32, 33 However, in outpatients with community-acquired respiratory tract infections such as acute exacerbations of chronic bronchitis and community-acquired pneumonia caused by S. pneumoniae, AUC 24h /MIC ratios of about ≥25 are predictive for bacterial eradication. 10, 34 Based on the tear concentrations measured in the healthy volunteer study by Raizman et al., 22 the calculated AUC over six hours after the instillation of a single dose (one drop) of 0.5% levofloxacin ophthalmic solution was more than two-fold higher than the AUC 24h after a single oral or intravenous administration of 750mg levofloxacin. In clinical practice the AUC should even be higher, as patients would receive multiple doses per day. These data indicate that a 0.5% levofloxacin ophthalmic solution is effective in the treatment of external ocular infections against target pathogens.
Clinical Trials
A topical ophthalmic solution of 0.5% levofloxacin was effective in bacterial conjunctivitis and keratitis. [35] [36] [37] [38] [39] In a study by Yactayo-Miranda et al., so far published only as a poster, 0.5% levofloxacin eye drops were also effective in the treatment of chronic bacterial blepharoconjunctivits. 40 More recently, there has been increasing interest in the use of levofloxacin as a prophylactic agent in intraocular surgery. Because of its broad spectrum of antibacterial activity and high corneal permeability, levofloxacin appears to be a suitable agent for this purpose as it has been shown to reduce the bacterial conjunctival load, being the main source of bacteria causing post-operative infections, and to achieve drug levels inside the eye that are capable of preventing infection in cases of contamination. [23] [24] [25] 41 Levofloxacin proved to be effective as prophylaxis in intraocular surgery and acted synergistically when combined with the standard conjunctival povidone-iodine irrigation. 42, 43 Recently, 0.5% levofloxacin eye drops were evaluated for the prevention of post-cataract surgery intraocular infection. In this large-scale Oftaquix® is a broad spectrum topical antibiotic that acts fast to kill bacteria without inhibition of wound healing. In fact, hard-hitting Oftaquix has been the anti-infective eye drops of choice in the ESCRS endophthalmitis study and the ESCRS Guidelines.
Oftaquix (Levofloxacin) Abbreviated Prescribing Information
Please refer to the full Summary of Product Characteristics before prescribing. Presentation: One ml Oftaquix eye drop solution contains 5.12 mg of levofloxacin hemihydrate equivalent to 5 mg of levofloxacin. Indications: Oftaquix is indicated for the topical treatment of bacterial external ocular infections in patients ≥1 year of age caused by levofloxacin susceptible microorganisms. Considerations should be given to official guidance on the appropriate use of antibacterial agents. Posology: Instil one to two drops in the affected eye(s) every two hours up to 8 times per day while awake for the first two days and then four times daily on days 3 through 5.
Contraindications: Hypersensitivity to the active substance levofloxacin, to other quinolones or to any of the excipients, e.g. benzalkonium chloride. Precautions/Warnings: Oftaquix must not be injected sub-conjunctivally. The solution should not be introduced directly into the anterior chamber of the eye. Systemic fluoroquinolones have been associated with hypersensitivity reactions, even following a single dose. If an allergic reaction to levofloxacin occurs, discontinue the medication. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Oftaquix 5 mg/ml eye drops in multi-dose bottles contains benzalkonium chloride, which may cause eye irritation. Oftaquix should be used during pregnancy and lactation only if the potential benefit justifies any potential risk to the foetus or the nursing child. Adverse Reactions: Approximately 10% of patients can be expected to experience adverse reactions. The reactions are usually graded as mild or moderate, are transient, and are generally restricted to the eye. The following undesirable effects assessed as definitely, probably or possibly related to treatment were reported during clinical trials and post-marketing experience with Oftaquix: Eye disorders Common (>1/100, <1/10): Ocular burning, decreased vision and mucous strand. Uncommon (>1/1,000, <1/100): Lid matting, chemosis, conjunctival papillary reaction, lid oedema, ocular discomfort, ocular itching, ocular pain, conjunctival injection, conjunctival follicles, ocular dryness, lid erythema, and photophobia. No corneal precipitates were observed in clinical studies. Immune system disorders Rare (>1/10,000, <1/1,000): extra-ocular allergic reactions, including skin rash. Very rare (< 1/10,000), <including isolated reports>: anaphylaxis. Nervous system disorders Uncommon (>1/1,000, <1/100): headache Respiratory, thoracic and mediastinal disorders Uncommon (>1/1,000, <1/100): rhinitis. Very rare (< 1/10,000), <including isolated reports>: Laryngeal oedema. Storage precautions: Multi-dose bottle: After first opening to be used within 28 days. Single-use containers: After first opening the pouch to be used within 3 months, after first use discard the opened single-use container with any remaining solution.
Pack sizes: 5 ml white LDPE bottle with a LDPE dropper tip and a tan HDPE screw cap. Oftaquix unpreserved unit-doses in LDPE single-dose containers as strips of ten containing 0.5 ml each, packed in a paper-coated aluminium-PE foil pouch. 
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